What Is Lysostaphin? Definition and What Research Reports
Lysostaphin is a bacterially produced peptidoglycan-degrading enzyme — a glycylglycine endopeptidase originally described from Staphylococcus simulans — that cleaves the glycine cross-bridges holding the Staphylococcus aureus cell wall together, causing the cell to lyse. In peptide and protein literature it is usually classed as an "enzybiotic" or protein antibiotic rather than a short signalling peptide. Published work has largely been laboratory and animal research on recombinant production, formulation, catheter coatings, engineered variants, and resistance. This entry is definitional only and describes what studies reported.
Lysostaphin is a bacterially produced, peptidoglycan-degrading enzyme that cuts the glycine-rich cross-bridges of the staphylococcal cell wall. Structural work characterising how the enzyme recognises and cleaves its target described lysostaphin as a glycylglycine endopeptidase that engages the cross-linking peptides of Staphylococcus aureus peptidoglycan, with substrate recognition and catalysis handled by distinct parts of the molecule (PMID 30018958). Because the cross-bridge composition it prefers is characteristic of staphylococci, the enzyme is widely described in the literature as a narrow-spectrum lytic agent rather than a broad antibacterial.
Molecular Class and Origin
Lysostaphin is a protein — specifically a hydrolytic enzyme — not a short synthetic peptide of the kind usually catalogued under "research peptides." It belongs to the family of bacteriocin-like peptidoglycan hydrolases, sometimes grouped with other lytic proteins under the informal label enzybiotics. The gene was originally identified in Staphylococcus simulans; a 2021 study cloned the S. simulans lysostaphin gene and expressed it in Bacillus subtilis WB600 as a recombinant production host (PMID 34708172). Other production work has focused on simplifying purification: researchers described a self-cleaving construct in which recombinant lysostaphin was released from a cellulose-binding-domain fusion partner (PMID 35790549).
How the Term Is Used
In the published literature, "lysostaphin" is used in three fairly distinct ways:
- As a named enzyme — the specific glycylglycine endopeptidase characterised in structural and kinetic studies (PMID 30018958).
- As a laboratory reagent — a standard tool for lysing staphylococcal cells, which is why methods papers have proposed standardised assays for measuring its enzymatic activity (PMID 33348544).
- As a scaffold for protein engineering — a starting sequence that investigators modify to change immunogenicity, specificity, or delivery, as in a deimmunised variant studied against methicillin-resistant S. aureus (MRSA) (PMID 33318001).
It is not a metabolic, growth-factor or signalling peptide, and the literature indexed here does not treat it as one.
What the Published Literature Reports
The verified studies below are laboratory (in vitro) or animal work. None of the papers listed on this page is a large human clinical trial, and this entry makes no claim about human outcomes.
Activity and conditions
A 2022 study examined how the surrounding chemistry changes enzyme behaviour and reported that sodium chloride concentration and pH influenced lysostaphin catalytic activity, its binding to bacterial cells, and its bacteriolytic effect (PMID 36112205). A separate methods paper set out a simple protocol for determining lysostaphin enzymatic activity, addressing the practical problem that activity values are otherwise difficult to compare between laboratories (PMID 33348544).
Engineered and formulated versions
Several groups have altered the protein or its delivery vehicle. Researchers described a deimmunised lysostaphin that synergised with small-molecule chemotherapies and resensitised MRSA to β-lactam antibiotics in their experiments (PMID 33318001). A 2021 paper reported development of a lysostaphin variant framed as "human skin microbiota-friendly," aimed at sparing commensal skin bacteria while retaining anti-staphylococcal activity (PMID 33932416). On the formulation side, a 2024 study encapsulated lysostaphin in PLGA nanoparticles and evaluated the resulting particles against S. aureus infection models (PMID 38782313), while a 2021 study built lung-targeting lysostaphin microspheres and tested them in the context of MRSA pneumonia treatment and prevention (PMID 34582183).
Surfaces and biofilms
Because staphylococci colonise implanted materials, part of the literature attaches the enzyme to surfaces instead of delivering it systemically. A 2024 study reported that a lysostaphin-functionalised silicone catheter prevented S. aureus biofilm formation in their test system (PMID 38048926), and a 2023 study loaded lysostaphin onto diopside powder and reported antibacterial and anti-biofilm properties for the loaded material (PMID 36839449).
Resistance
Resistance is an active topic: a 2026 report described a novel endopeptidase developed to overcome lysostaphin resistance, indicating that staphylococcal resistance to the parent enzyme is a recognised limitation in this research area (PMID 42259805).
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeSummary Table of Cited Work
| Focus | Year / Journal | What researchers reported |
|---|---|---|
| Substrate interaction | 2018, Frontiers in Molecular Biosciences | Structural and functional analysis of how lysostaphin engages its peptidoglycan substrate (PMID 30018958) |
| Activity assay | 2020, Antibiotics | A simple protocol for determining lysostaphin enzymatic activity (PMID 33348544) |
| Recombinant expression | 2021, AIMS Microbiology | Cloning and expression of the S. simulans lysostaphin gene in B. subtilis WB600 (PMID 34708172) |
| Deimmunised variant | 2021, AAC | Synergy with small-molecule chemotherapies and resensitisation of MRSA to β-lactams (PMID 33318001) |
| Microbiota-sparing variant | 2021, IJBM | A skin-microbiota-friendly lysostaphin design (PMID 33932416) |
| Inhaled/lung delivery | 2021, ACS Nano | Lung-targeting microspheres studied for MRSA pneumonia treatment and prevention (PMID 34582183) |
| Buffer conditions | 2022, AMB | NaCl and pH influenced catalytic activity, cell binding and bacteriolysis (PMID 36112205) |
| Purification strategy | 2022, AMB | Self-cleaved release of recombinant lysostaphin from a cellulose-binding-domain fusion (PMID 35790549) |
| Bioceramic carrier | 2023, Pathogens | Antibacterial and anti-biofilm properties of lysostaphin-loaded diopside powder (PMID 36839449) |
| Device coating | 2024, IJBM | Lysostaphin-functionalised silicone catheter prevented S. aureus biofilm (PMID 38048926) |
| Nanoparticle carrier | 2024, IJBM | PLGA nanoparticle-encapsulated lysostaphin evaluated against S. aureus infection (PMID 38782313) |
| Resistance | 2026, Scientific Reports | A novel endopeptidase described as overcoming lysostaphin resistance (PMID 42259805) |
Lysostaphin Tolerability: What Studies Report
The verified literature summarised here is preclinical, and none of these papers is presented as a human safety trial, so no adverse-event profile in people can be drawn from them. Two themes in the cited work do touch on tolerability concerns indirectly: immunogenicity, which motivated the deimmunised variant researchers tested against MRSA (PMID 33318001), and collateral effects on non-target bacteria, which motivated the skin-microbiota-friendly variant reported in 2021 (PMID 33932416). Loss of activity through bacterial resistance is a separate limitation, and a 2026 report described an alternative endopeptidase intended to overcome it (PMID 42259805).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appRelated Terms
- Enzybiotic — an umbrella term for enzymes, including lysostaphin, used as antibacterial agents.
- Peptidoglycan hydrolase — the broader enzyme class that cleaves bacterial cell wall polymers.
- Endolysin — bacteriophage-derived lytic enzymes often discussed alongside lysostaphin, though lysostaphin itself is bacterially encoded.
- Bacteriocin — a bacterially produced antibacterial protein or peptide; lysostaphin is frequently grouped here.
This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or treatment decision. Lysostaphin preparations described in the cited literature were used in laboratory and animal research settings, and this entry describes only what the study authors reported.
References
- Structural and Functional Insights Into Lysostaphin-Substrate Interaction (Frontiers in Molecular Biosciences, 2018)
- A Simple Protocol for the Determination of Lysostaphin Enzymatic Activity (Antibiotics, 2020)
- Deimmunized Lysostaphin Synergizes with Small-Molecule Chemotherapies and Resensitizes Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics (Antimicrobial Agents and Chemotherapy, 2021)
- Human skin microbiota-friendly lysostaphin (International Journal of Biological Macromolecules, 2021)
- Lung-Targeting Lysostaphin Microspheres for Methicillin-Resistant Staphylococcus aureus Pneumonia Treatment and Prevention (ACS Nano, 2021)
- Cloning and expression of Staphylococcus simulans lysostaphin enzyme gene in Bacillus subtilis WB600 (AIMS Microbiology, 2021)
- Influence of NaCl and pH on lysostaphin catalytic activity, cell binding, and bacteriolytic activity (Applied Microbiology and Biotechnology, 2022)
- Self-cleaved expression of recombinant lysostaphin from its cellulose binding domain fusion (Applied Microbiology and Biotechnology, 2022)
- Antibacterial and Anti-Biofilm Properties of Diopside Powder Loaded with Lysostaphin (Pathogens, 2023)
- Efficacy of Lysostaphin functionalized silicon catheter for the prevention of Staphylococcus aureus biofilm (International Journal of Biological Macromolecules, 2024)
- PLGA nanoparticle-encapsulated lysostaphin for the treatment of Staphylococcus aureus infections (International Journal of Biological Macromolecules, 2024)
- Novel endopeptidase overcoming lysostaphin resistance (Scientific Reports, 2026)
Frequently asked questions
What kind of molecule is lysostaphin?▾
It is a protein enzyme rather than a short synthetic peptide. Structural work characterised lysostaphin as a glycylglycine endopeptidase that recognises and cleaves cross-linking peptides in staphylococcal cell wall peptidoglycan (PMID 30018958). It is commonly grouped with bacteriocins and peptidoglycan hydrolases, sometimes under the informal label enzybiotic, because its antibacterial action is enzymatic rather than receptor-mediated.
Where does lysostaphin come from?▾
The enzyme was originally described from Staphylococcus simulans. A 2021 study cloned the S. simulans lysostaphin gene and expressed it recombinantly in Bacillus subtilis WB600 (PMID 34708172). A separate 2022 paper described a self-cleaving cellulose-binding-domain fusion strategy for releasing recombinant lysostaphin during purification (PMID 35790549). Most material used in research is therefore recombinant rather than natively harvested.
What has research reported about lysostaphin and MRSA?▾
Researchers reported that a deimmunised lysostaphin variant synergised with small-molecule chemotherapies and resensitised methicillin-resistant Staphylococcus aureus to β-lactam antibiotics in their experiments (PMID 33318001). A separate 2021 study developed lung-targeting lysostaphin microspheres and evaluated them in the context of MRSA pneumonia treatment and prevention (PMID 34582183). Both were laboratory and animal investigations, not human clinical trials.
Why do studies attach lysostaphin to surfaces or particles?▾
To concentrate the enzyme where staphylococci colonise. A 2024 study reported that a lysostaphin-functionalised silicone catheter prevented Staphylococcus aureus biofilm formation in its test system (PMID 38048926), and a 2023 study reported antibacterial and anti-biofilm properties for diopside powder loaded with lysostaphin (PMID 36839449). Another 2024 paper encapsulated the enzyme in PLGA nanoparticles for S. aureus infection models (PMID 38782313).
Can bacteria become resistant to lysostaphin?▾
Resistance is treated as a real limitation in this literature. A 2026 report described a novel endopeptidase developed specifically to overcome lysostaphin resistance, which implies that resistant staphylococci have been observed in research settings (PMID 42259805). Changes in the cell wall cross-bridge structure that lysostaphin targets are the general mechanism discussed in structural studies of substrate interaction (PMID 30018958).
Does buffer chemistry affect lysostaphin activity in experiments?▾
Yes. A 2022 study reported that sodium chloride concentration and pH influenced lysostaphin catalytic activity, binding to bacterial cells, and bacteriolytic activity (PMID 36112205). Because activity values vary with conditions and assay design, a 2020 methods paper proposed a simple standardised protocol for determining lysostaphin enzymatic activity so results can be compared across laboratories (PMID 33348544).
What do the cited studies say about safety?▾
The verified papers summarised here are preclinical, so they do not establish a human adverse-event profile. Two lines of work address tolerability indirectly: a deimmunised variant designed to reduce immune recognition (PMID 33318001) and a lysostaphin engineered to be friendlier to human skin microbiota, sparing commensal organisms (PMID 33932416). This information is educational only and is not medical advice.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.